Technical Analysis for FGEN - FibroGen, Inc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Expansion Breakdown | Bearish Swing Setup | -13.69% | |
| Volume Surge | Other | -13.69% |
| Alert | Time |
|---|---|
| Down 1 ATR | about 6 hours ago |
| Down 10% | about 9 hours ago |
| 60 Minute Opening Range Breakdown | about 9 hours ago |
| 1.5x Volume Pace | about 10 hours ago |
| Down 5% | about 10 hours ago |
Get a Trading Assistant
- Earnings date: 08/05/2024
FibroGen, Inc Description
FibroGen, Inc. operates as a research-based biopharmaceutical company in the United States. The company focuses on the discovery, development, and commercialization of therapeutic agents to treat serious unmet medical needs. The company develops roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019, a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. It also focuses on use of the proprietary type III recombinant human collagens in its biosynthetic corneal implant product candidate, FG-5200 for the treatment of corneal blindness. The company was incorporated in 1993 and is headquartered in San Francisco, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Clinical Development Monoclonal Antibody Kidney Disease Pancreatic Cancer Anemia Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Chronic Kidney Disease Blindness Cornea Collagen Liver Fibrosis Treatment Of Idiopathic Pulmonary Fibrosis Hypoxia Inducible Factors
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.015 |
| 52 Week Low | 0.3345 |
| Average Volume | 2,739,611 |
| 200-Day Moving Average | 1.16 |
| 50-Day Moving Average | 1.14 |
| 20-Day Moving Average | 1.10 |
| 10-Day Moving Average | 1.04 |
| Average True Range | 0.11 |
| RSI (14) | 28.06 |
| ADX | 17.21 |
| +DI | 17.37 |
| -DI | 34.54 |
| Chandelier Exit (Long, 3 ATRs) | 1.15 |
| Chandelier Exit (Short, 3 ATRs) | 1.09 |
| Upper Bollinger Bands | 1.32 |
| Lower Bollinger Band | 0.89 |
| Percent B (%b) | -0.27 |
| BandWidth | 39.24 |
| MACD Line | -0.07 |
| MACD Signal Line | -0.05 |
| MACD Histogram | -0.027 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.00 | ||||
| Resistance 3 (R3) | 1.02 | 0.97 | 0.96 | ||
| Resistance 2 (R2) | 0.97 | 0.91 | 0.96 | 0.95 | |
| Resistance 1 (R1) | 0.87 | 0.87 | 0.84 | 0.85 | 0.94 |
| Pivot Point | 0.81 | 0.81 | 0.80 | 0.80 | 0.81 |
| Support 1 (S1) | 0.72 | 0.76 | 0.69 | 0.69 | 0.60 |
| Support 2 (S2) | 0.66 | 0.72 | 0.65 | 0.59 | |
| Support 3 (S3) | 0.56 | 0.66 | 0.58 | ||
| Support 4 (S4) | 0.54 |
